Discover
AMLX
Amylyx Pharmaceuticals, Inc.
32.41
2 x 23.92
1 x 33.74
bid
ask
-
1.53
4.51%
2 @ 07:30 PM
32.54 +0.13 (0.40%)
| Ytd | 168.29% | |
| 1y | 144.60% |
32.25
day range
34.21
11.38
52 week range
39.66
| Open | 34.21 | Prev Close | 33.94 | Low | 32.25 | High | 34.21 | Mkt Cap | 4.14B |
| Vol | 2.05M | Avg Vol | 2.48M | EPS | -1.41 | P/E | N/A | Forward P/E | -28.07 |
| Beta | -0.12 | Short Ratio | 3.40 | Inst. Own | 94.06% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 26.60 | 200-d Avg | 17.60 | 1yr Est | 42.36 |
| Income Statement | |||
| Operating Expenses | 45.69M | ||
| Research and Development Expense | 23.77M | ||
| Selling, General and Administrative Expense | 21.93M | ||
| Operating Income | -45.69M | ||
| Net Income | -43.42M | ||
| Net Income Common Stock | -43.42M | ||
| Net Income Common Stock (USD) | -43.42M | ||
| Consolidated Income | -43.42M | ||
| Earnings per Basic Share | -0.39 | ||
| Earnings per Basic Share (USD) | -0.39 | ||
| Earnings per Diluted Share | -0.39 | ||
| Earning Before Interest & Taxes (EBIT) | -43.42M | ||
| Earning Before Interest & Taxes (USD) | -43.42M | ||
| Weighted Average Shares | 111.20M | ||
| Weighted Average Shares Diluted | 111.20M | ||
| Balance Sheet | |||
| Cash and Equivalents | 50.31M | ||
| Cash and Equivalents (USD) | 50.31M | ||
| Investments | 201.43M | ||
| Investments Current | 201.43M | ||
| Current Assets | 256.34M | ||
| Property, Plant & Equipment Net | 4.74M | ||
| Total Assets | 264.56M | ||
| Debt Current | 1.01M | ||
| Total Debt | 5.26M | ||
| Current Liabilities | 21.15M | ||
| Debt Non-Current | 4.25M | ||
| Total Liabilities | 25.40M | ||
| Accumulated Retained Earnings (Deficit) | -836.13M | ||
| Accumulated Other Comprehensive Income | 19.00K | ||
| Shareholders Equity | 239.17M | ||
| Shareholders Equity (USD) | 239.17M | ||
| Assets Non-Current | 8.23M | ||
| Total Debt (USD) | 5.26M | ||
| Liabilities Non-Current | 4.25M | ||
| Trade and Non-Trade Payables | 5.53M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 43.00K | ||
| Net Cash Flow from Financing | 1.48M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -179.81M | ||
| Capital Expenditure | -30.00K | ||
| Issuance (Purchase) of Equity Shares | 1.97M | ||
| Net Cash Flow from Investing | -149.80M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -149.77M | ||
| Net Cash Flow from Operations | -31.42M | ||
| Effect of Exchange Rate Changes on Cash | -68.00K | ||
| Share Based Compensation | 8.32M | ||